MX2019014831A - Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9. - Google Patents

Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9.

Info

Publication number
MX2019014831A
MX2019014831A MX2019014831A MX2019014831A MX2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A MX 2019014831 A MX2019014831 A MX 2019014831A
Authority
MX
Mexico
Prior art keywords
methods
administering
diabetic patients
pcsk9 inhibitor
treating hyperlipidemia
Prior art date
Application number
MX2019014831A
Other languages
English (en)
Spanish (es)
Inventor
Bujas-Bobanovic Maja
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Priority claimed from PCT/IB2018/054182 external-priority patent/WO2018225041A1/en
Publication of MX2019014831A publication Critical patent/MX2019014831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2019014831A 2017-06-09 2018-06-09 Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9. MX2019014831A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762517672P 2017-06-09 2017-06-09
US201762532162P 2017-07-13 2017-07-13
EP18305565 2018-05-04
PCT/IB2018/054182 WO2018225041A1 (en) 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Publications (1)

Publication Number Publication Date
MX2019014831A true MX2019014831A (es) 2020-02-13

Family

ID=62815099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014831A MX2019014831A (es) 2017-06-09 2018-06-09 Metodos para el tratamiento de la hiperlipidemia en pacientes diabeticos administrando un inhibidor de pcsk9.

Country Status (9)

Country Link
EP (1) EP3634469A1 (OSRAM)
JP (2) JP2020522544A (OSRAM)
KR (1) KR20200026826A (OSRAM)
CN (1) CN110913889A (OSRAM)
AU (1) AU2018280567A1 (OSRAM)
CA (1) CA3066317A1 (OSRAM)
IL (2) IL314423A (OSRAM)
MX (1) MX2019014831A (OSRAM)
TW (2) TW202310872A (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
CN113876956B (zh) * 2020-07-01 2023-07-04 陈敏 Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用
CN114525258A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用
WO2023051822A1 (zh) * 2021-09-30 2023-04-06 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸
WO2023104051A1 (zh) * 2021-12-07 2023-06-15 广州嘉越医药科技有限公司 吲哚取代四氢异喹啉类化合物与他汀类化合物的联合应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20150283236A1 (en) * 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
JP6912374B2 (ja) * 2014-07-16 2021-08-04 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法
CN107206068A (zh) * 2014-07-16 2017-09-26 赛诺菲生物技术公司 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
KR20240172758A (ko) * 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체

Also Published As

Publication number Publication date
TW201904608A (zh) 2019-02-01
IL314423A (en) 2024-09-01
JP2020522544A (ja) 2020-07-30
IL271212B1 (en) 2024-08-01
RU2019144346A3 (OSRAM) 2021-10-13
TW202310872A (zh) 2023-03-16
JP2023123842A (ja) 2023-09-05
CN110913889A (zh) 2020-03-24
EP3634469A1 (en) 2020-04-15
IL271212B2 (en) 2024-12-01
AU2018280567A1 (en) 2020-01-23
RU2019144346A (ru) 2021-07-09
IL271212A (en) 2020-01-30
KR20200026826A (ko) 2020-03-11
CA3066317A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JOP20230124A1 (ar) تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
UA117570C2 (uk) Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX381780B (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo.
EP4424324A3 (en) Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
CY1111595T1 (el) Τροποποιηση της θεραπειας με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια
EA201692282A1 (ru) Композиция для лечения сахарного диабета, содержащая инсулин и двойной агонист glp-1/глюкагона
MX2010006823A (es) Metodos para el tratamiento de la gota.
FI20135152A7 (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
MX2021004994A (es) Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
IL271212A (en) Methods for treating excess blood fat in diabetic patients by administering a pcsk9 inhibitor
MX2021003349A (es) Proteina de fusion glp1-fc y conjugado de la misma.
MX2025006068A (es) Proteina de union cldn18.2/4-1bb y su uso medico
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2022006812A (es) Metodos para tratar epoc mediante la administracion de un antagonista de il-33.
MY200701A (en) Method of averting opioid addiction
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
EA202092978A2 (ru) Фармацевтическая композиция для парентерального капельного введения
RU2018147275A (ru) Способ лечения сахарного диабета 2 типа у больных со стеатогепатитом